Taglich's Company Profile for:

Receive email alerts  for this company		Navidea Biopharmaceuticals
		Symbol: NAVB Analyst: John Nobile Taglich Rating: Speculative Buy Price Target: $3.00 Time Horizon: 12 Months Rating Established: November 18, 2011 Price When Established: $2.26 Most Recent Report: November 18, 2011 Price When Issued: $2.26

*The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statements are the opinion of Taglich Brothers, Inc. and are not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in the reports are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance. All research issued by Taglich Brothers, Inc. is based on public information. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned and was not a manager or co-manager of any offering for the company within the last three years. The company paid a monetary fee of $12,000 (USD) on April 2009 and will pay $12,000 (USD) on February 2010 for the creation and dissemination of research reports for the first eighteen months. After the first eighteen months of publication, the company will pay a monthly monetary fee of $2,000 (USD) to Taglich Brothers, Inc., for the creation and dissemination of research reports. For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.